- Home
- / Clovis Oncology
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Clovis Oncology financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2023-02-21
Market Capitalization
$10.6 M
2023-02-21
Revenue
$148.8 M
FY, 2021
CreditSafe Score
?
Score changed on Dec 13, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.6M | 78.0K | 55.5M | 95.4M | 143.0M | 164.5M | 148.8M | |||
| Revenue growth, % | -100.0% | |||||||||
| General and administrative expense | 10.6M | 16.6M | 21.5M | 30.5M | 40.7M | 138.9M | 175.8M | 182.8M | 163.9M | 128.4M |
| Operating expense total | 69.5M | 83.1M | 159.2M | 299.8M | 291.9M | 281.4M | 407.1M | 475.6M | 425.4M | |
| EBIT | (73.8M) | (83.8M) | (158.5M) | (376.7M) | (372.7M) | (237.6M) | (333.8M) | (376.7M) | (302.2M) | (225.8M) |
| EBIT margin, % | -1163.0% | -477862.8% | -428.1% | -350.0% | -263.4% | -183.7% | ||||
| Interest expense | 2.6M | 8.4M | 8.5M | 112.3M | 33.6M | 21.9M | ||||
| Pre tax profit | (74.0M) | (84.5M) | (157.7M) | (381.9M) | (381.2M) | (350.0M) | (367.4M) | (398.6M) | (369.8M) | (264.9M) |
| Income tax expense | (27.0K) | (52.0K) | (2.3M) | 29.1M | 32.0M | (3.6M) | 608.0K | 1.8M | (547.0K) | (404.0K) |
| Net Income | (74.0M) | (84.5M) | (160.0M) | (352.9M) | (349.1M) | (346.4M) | (368.0M) | (400.4M) | (369.2M) | (264.5M) |